20276-55-5

Basic information

• Product Name: 1-methylidenepiperidinium chloride
• Synonyms: Piperidinium, 1-methylene-, chloride
• CAS NO: 20276-55-5
• Molecular Formula: C₆H₁₂N*Cl
• Molecular Weight: 133.6192
• Mol File: 20276-55-5.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 1-methylidenepiperidinium chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-methylidenepiperidinium chloride(20276-55-5)
• EPA Substance Registry System: 1-methylidenepiperidinium chloride(20276-55-5)

Safety Data

• Hazardous Substances Data: 20276-55-5(Hazardous Substances Data)

Upstream product

• 3275-13-6 1-(ethoxymethyl)piperidine 
• 880-09-1 di(N-piperidinyl)methane 
• 110-89-4 piperidine 
• 7647-01-0 hydrogenchloride 
• 75-09-2 dichloromethane 
• 56-23-5 tetrachloromethane 
• 7782-50-5 chlorine 
• 60-29-7 diethyl ether 
• 50-00-0 formaldehyd 

Downstream Products

• 4756-86-9 2-Piperidinomethyl-indan-1-on 
• 73-63-2 1-phenyl-3-(piperidin-1-yl)propan-1-one 
• 96705-55-4 NiCl₂CH₂(CH₂CH₂)2NCH₂CH₂N(CH₂CH₂)2CH₂ 
• 133931-20-1 1-Benzyl-4-iodo-3-(2-piperidin-1-yl-ethyl)-1H-indole 

Relevant articles and documents

A New Convenient Synthesis of Dialkyl(methylene)ammonium Chloride

A new, convenient synthesis of dialkyl(methylene)ammonium chloride is proposed from gem-aminoethers and methyltrichlorosilane, a by-product of the industrial methylchlorosilane synthesis.

Substituted Sulfonamide Compounds

Substituted sulfonamide compounds corresponding to the formula I wherein m, n, p, Q, R1, R2, R3, R4, X, Y and Z have the respective meanings defined herein, pharmaceutical compositions containing such compounds, a process for their preparation, and the use of such compounds for the treatment and/or inhibition of pain and other conditions mediated by bradykinin receptor 1 (B1R) and/or bradykinin receptor 2 (B2R).

Hypolipidemic effects of α, β, and γ-alkylaminophenone analogs in rodents

A number of N-substituted β-alkylaminophenone derivatives including two (α- and two γ-alkylaminophenone analogs were synthesized and investigated for hypolipidemic activity in mice at 8 mg/kg/day ip. Most of these analogs were found to be significantly more active than lovastatin and clofibrate. N-Phenylpiperazinopropiophenone 16 was one of the best derivatives, lowering serum cholesterol levels 41% and serum triglyceride levels 48% after 16 days of drug administration in CF1 mice. In Sprague-Dawley rats, N-phenylpiperazinopropiophenone at 8 mg/kg/day orally also demonstrated more potent hypolipidemic activity than clofibrate, gemfibrozil, and lovastatin at their therapeutic dosage. It significantly reduced tissue cholesterol and triglyceride levels in the aorta wall tissue and lowered the cholesterol and triglyceride levels in chylomicron, very low density lipid (VLDL) and low density lipid (LDL) fractions, while it significantly elevated the cholesterol levels in high density lipid (HDL) fraction. This compound also proved to be active in lowering both cholesterol and triglyceride levels in hyperlipidemic mice and rats induced with atherogenic diet. In vitro liver acetyl coenzyme A (CoA) synthetase, 3-hydroxy-3-methyl glutaryl (HMG) CoA reductase, acyl CoA cholesterol acyl transferase (ACAT), sn-glycerol-3-phosphate acyltransferase, phosphatidylate phosphohydrolase, and hepatic lipoprotein lipase activities were significantly inhibited by N-phenylpiperazinopropiophenone from 25 to 100 μM.